Literature DB >> 21820041

Multi-drug delivery to tumor cells via micellar nanocarriers.

Usha Katragadda1, Quincy Teng, Bindhu Madhavi Rayaprolu, Thripthy Chandran, Chalet Tan.   

Abstract

The aim of this study was to develop micellar nanocarriers for concomitant delivery of paclitaxel and 17-allylamino-17-demethoxygeldanamycin (17-AAG) for cancer therapy. Paclitaxel and 17-AAG were simultaneously loaded into polymeric micelles by a solvent evaporation method. Two candidate nanocarrier constructs, polyethylene glycol-poly(D, L-lactic acid) (PEG-PLA) micelles and PEG-distearoylphosphatidylethanolamine/tocopheryl polyethylene glycol 1000 (PEG-DSPE/TPGS) mixed micelles, were assessed for the release kinetics of the loaded drugs. Compared to PEG-PLA micelles, entrapment of paclitaxel and 17-AAG into PEG-DSPE/TPGS mixed micelles resulted in significantly prolonged release half-lives. The simultaneous incorporation of paclitaxel and 17-AAG into PEG-DSPE/TPGS mixed micelles was confirmed by (1)H NMR analysis. Paclitaxel/17-AAG-loaded PEG-DSPE/TPGS mixed micelles were as effective in blocking the proliferation of human ovarian cancer SKOV-3 cells as the combined free drugs. PEG-DSPE/TPGS mixed micelles may provide a novel and advantageous delivery approach for paclitaxel/17-AAG combination therapy.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21820041      PMCID： PMC3186853          DOI： 10.1016/j.ijpharm.2011.07.033

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


  22 in total

Review 1.  Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery.

Authors:  Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  Pharmacol Ther       Date:  2006-07-11       Impact factor: 12.310

2.  Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT.

Authors:  Nivedita Sain; Bhavani Krishnan; Michael G Ormerod; Assunta De Rienzo; Wai M Liu; Stanley B Kaye; Paul Workman; Ann L Jackman
Journal:  Mol Cancer Ther       Date:  2006-05       Impact factor: 6.261

3.  Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

Authors:  Paul G Richardson; Asher A Chanan-Khan; Melissa Alsina; Maher Albitar; David Berman; Marianne Messina; Constantine S Mitsiades; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2010-07-07       Impact factor: 6.998

4.  Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.

Authors:  M J Egorin; E G Zuhowski; D M Rosen; D L Sentz; J M Covey; J L Eiseman
Journal:  Cancer Chemother Pharmacol       Date:  2001-04       Impact factor: 3.333

5.  Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.

Authors:  David B Solit; Andrea D Basso; Adam B Olshen; Howard I Scher; Neal Rosen
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

6.  Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

Authors:  Tae-You Kim; Dong-Wan Kim; Jae-Yong Chung; Sang Goo Shin; Sung-Chul Kim; Dae Seog Heo; Noe Kyeong Kim; Yung-Jue Bang
Journal:  Clin Cancer Res       Date:  2004-06-01       Impact factor: 12.531

Review 7.  Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.

Authors:  Windy Dean-Colomb; Francisco J Esteva
Journal:  Semin Oncol       Date:  2008-04       Impact factor: 4.929

8.  Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer.

Authors:  D-W Kim; S-Y Kim; H-K Kim; S-W Kim; S W Shin; J S Kim; K Park; M Y Lee; D S Heo
Journal:  Ann Oncol       Date:  2007-09-04       Impact factor: 32.976

9.  Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.

Authors:  Ayana Sawai; Sarat Chandarlapaty; Heidi Greulich; Mithat Gonen; Qing Ye; Carlos L Arteaga; William Sellers; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2008-01-15       Impact factor: 12.701

10.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Authors:  Shanu Modi; Alison T Stopeck; Michael S Gordon; David Mendelson; David B Solit; Rochelle Bagatell; Weining Ma; Jennifer Wheler; Neal Rosen; Larry Norton; Gillian F Cropp; Robert G Johnson; Alison L Hannah; Clifford A Hudis
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544
View more
  12 in total

1.  A large-inner-diameter multi-walled carbon nanotube-based dual-drug delivery system with pH-sensitive release properties.

Authors:  Tao Yang; Zhenzhen Wu; Pingting Wang; Tingting Mu; Han Qin; Zhimin Zhu; Jian Wang; Lei Sui
Journal:  J Mater Sci Mater Med       Date:  2017-06-06       Impact factor: 3.896

Review 2.  Polymeric micelles for multi-drug delivery in cancer.

Authors:  Hyunah Cho; Tsz Chung Lai; Keishiro Tomoda; Glen S Kwon
Journal:  AAPS PharmSciTech       Date:  2014-12-11       Impact factor: 3.246

Review 3.  Emerging concepts in designing next-generation multifunctional nanomedicine for cancer treatment.

Authors:  Kasturee Chakraborty; Archana Tripathi; Sukumar Mishra; Argha Mario Mallick; Rituparna Sinha Roy
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

4.  Combination drug delivery approaches in metastatic breast cancer.

Authors:  Jun H Lee; Anjan Nan
Journal:  J Drug Deliv       Date:  2012-04-26

5.  Long-term effect of ropivacaine nanoparticles for sciatic nerve block on postoperative pain in rats.

Authors:  Zi Wang; Haizhen Huang; Shaozhong Yang; Shanshan Huang; Jingxuan Guo; Qi Tang; Feng Qi
Journal:  Int J Nanomedicine       Date:  2016-05-17

6.  Micellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis.

Authors:  Evgenii Skurikhin; Pavel Madonov; Olga Pershina; Natalia Ermakova; Angelina Pakhomova; Darius Widera; Edgar Pan; Mariia Zhukova; Lubov Sandrikina; Andrey Artamonov; Alexander Dygai
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

7.  Combined delivery of paclitaxel and tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis.

Authors:  Usha Katragadda; Wei Fan; Yingzhe Wang; Quincy Teng; Chalet Tan
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

8.  Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.

Authors:  Yingzhe Wang; Wei Fan; Xin Dai; Usha Katragadda; DeAngelo Mckinley; Quincy Teng; Chalet Tan
Journal:  Mol Pharm       Date:  2014-03-10       Impact factor: 4.939

9.  Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.

Authors:  Raghavendra Gowda; Nathan R Jones; Shubhadeep Banerjee; Gavin P Robertson
Journal:  J Nanomed Nanotechnol       Date:  2013-12

10.  A novel temperature-responsive micelle for enhancing combination therapy.

Authors:  Cheng-Liang Peng; Yuan-I Chen; Hung-Jen Liu; Pei-Chi Lee; Tsai-Yueh Luo; Ming-Jium Shieh
Journal:  Int J Nanomedicine       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.